SELUTION SLR PTA Drug Eluting Balloon

The SELUTION SLR™ Drug-Eluting Balloon (DEB) is the next step in the evolution of Leave Nothing Behind with Sustained Limus Release.

Real-World Evidence. Proven Results

The SUCCESS PTA Study is a multi-center prospective, observational evaluation of a real-world, real-practice PAD population over 12 months using the SELUTION SLR DEB in 723 patients across 27 sites in Europe, Asia, and South America. 

Patient Characteristics​​

  • Patient Disease Type: 74.2% Claudicant, 25.8% CLTI​​
  • Diabetes: 37.9%
  • Renal failure: 16.8%
  • CTO: 42.1%
  • Mean lesion length: 12.8 cm​​
  • Severe calcification: 16.3%​​

 

SUCCESS PTA Study Summary

The SELUTION JAPAN SFA Trial is a multi-center prospective, single-arm  evaluation of real-world superficial femoral artery PAD population up to 36 months of  SELUTION SLR DEB in 134 patients across 13 sites in Japan. 

Patient Characteristics​​

  • Diabetes: 60.3%
  • CTO: 17.2%
  • Severe calcification: 11.2%
  • Mean lesion length: 12.7 cm​​
SELUTION Japan SFA Trial Summary

The New Paradigm for Peripheral Interventions

Breakthrough Technology1 to deliver sustained limus release. 

PHOSPHOLIPID COATING

A phospholipid blend containing and protecting MicroReservoirs, each incorporated with a 1 μg/mm²  Sirolimus dose.

MICRORESERVOIRS

With a single intervention, millions of MicroReservoirs deliver a sustained and consistent drug release at a therapeutic level.
 

1. SELUTION SLR DEB was the first Sirolimus Drug-Eluting Balloon, for BTK, to be awarded Breakthrough Device designation by the US Food and Drug Administration.

SIZE MATRIX

SELUTION SLR DEB offers a broad portfolio to extend treatment options for peripheral artery disease

Advanced Coating Technology

Better Uniformity and Smaller Particle Size2

  • Durable coating resulting in limited drug loss

CAT contains and protects microreservoirs.  The coating is transferred to the vessel wall

  • Small homogenous particles

MicroReservoirs (~4 mm) are as small or smaller than red blood cells

  • Sirolimus proven safety profile

No local toxic effect on distal tissues/organs

 

2. Med Alliance 2024 Data on file.

Dr. Palena BTK CLI and Drug Eluting Balloons

Dr. Palena's (Italy) case review of BTK CLI treatment with SELUTION SLR PTA Balloons.

Prof. Rammos SFA and BTK with Limus-Eluting Balloons

Prof. Rammos (Germany) discusses the use of Limus-eluting ballons for SFA and BTK lesions.

Dr. Lichtenberg - SUCCESS 6-month Results

Dr. Lichtenberg discusses the results of the SUCCESS six-month all-comers registry at CIRSE 2024 after the late-breaking results were presented in the First @CIRSE session

Advancing Drug-Eluting Balloon Education

Advanced Workshop CLI and Revascularization Management, November 2023, Abano Terme, Italy
How to maximize DEB benefits: a case based practical guide in lower limbs,CIRSE congress, September 2023, Denmark
How I treat CLTI patients with novel Sirolimus DEB: DEB session, PAIRS 2024 conference, February 2024, UAE
Managing CLI patients: From vessel preparation techniques to treatment with sirolimus DEBs, DEB session, LINC congress, May 2024, Germany

Empowering healthcare practitioners through professional education initiatives, workshops and webinars

Resources

Customer Service and Ordering Information

For country-specific contact details, please see this page.